US ERA ARCHIVE DOCUMENT

3, 24-83 BO-1061



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY WASHINGTON, D.C. 20460

002620

OFFICE OF PESTICIDES AND TOXIC SUBSTANCES

MEMORANDUM

TO:

R. J. Taylor/V. Walters,

Product Managers, Team #25

Registration Division (TS-767)

THRU:

Edwin R. Budd, Section Head

Section II. Toxicology Branch

Hazard Evaluation Division (TS-769)

THRU:

Orville E. Paynter, Branch Chief

Toxicology Branch

Hazard Evaluation Division (TS-769)

SUBFOCT:

Study Entitled "Human Percutaneous Absorption of Paraquat", Conducted for Chevron Chemical Company by Howard I. Maibach, M.D., University of California Medical Center, San Francisco; September 24, 1982. EPA Accession No. 249511, EPA Record No. 91977.

TOX Chem No. 634

This submission consists of 4 individual studies: one study with Rhesus monkeys in which urinary excretion of the injected (i.m.) $^{14}\text{C-}$ paraquat dichloride was studied; and three studies with adult hyman males in which the dermal absorption of 14c-paraquat dichloride was investigated. Dermal absorption was determined by measuring total radioactivity in urine.

Monkeys eliminated 58.6% of the administered radioactivity in urine within 7 days after dosing. Most of this radioactivity was excreted within the first 24 hours after dosing.

Dermal absorption of 14C-paraguat dichloride by human males was very low. Only 0.230, 0.285 and 0.295% of the applied dose was absorbed through the skin of their hands, legs and forearms, respectively, during 5 days after dosing.

The study with monkeys was evaluated separately by Toxicology Branch/HED. Because the only difference in conducting of the three dermal absorption studies was an application site, these studies were evaluated together.

Due to insufficient experimental details, each study was classified as Acceptable as Supplementary. There are no core criteria for these types of studies.

Krystyna K. Locke, Ph.D.

Toxicology Branch

Hazard Evaluation Division (TS-769)

002620

Study Type: Metabolism

Accession Number: 249511

Sponsor: Chevron Chemical Company

Contracting Lab: Howard I. Maibach, M.D.

University of California Medical Center

San Francisco 94143

Date: September 24, 1982

Test Material: 14C-Paraquat Exchloride

Protocol:

single doses of 14C-paraquae dichloride (4.72 uCi equivalent to 607 ug; Specific Armivity = 2 mCi/mM; MW 272.2) were injected intramuscularly into the thighs of 4 adult, male Rhesus monkeys. Urine samples were confected daily for 7 days and assayed for 14C, using an internal standard and a liquid scintilation spectrophotometer. The first sample was assayed 24 hours after dosing.

Nothing was reported about the radiopurity of the test material and where it was labeled (in the methyl groups or in the ring); about the housing and feeding of the animals; and about the collection, storage and preservation of urine before the analyses.

There is also an error in the <u>Procedures</u> section of the submitted report. According to the <u>author</u>, a stock solution contained 2.4 ug of paraquat ion/ml. If this were correct, then a 0.25 ml dose would have contained 6.44 uCi of paraquat dichloride and not 4.72 uCi, as was reported by the author. A dose of 4.67 uCi (which is close to 4.72 uCi) can only be obtained if a stock solution contained 2.4 mg of paraquat dichloride/ml. (Calculations are attached.)

Results:

Most of the radioactivity (43.5-51.5% of the administered dose; average: 47.0%) was excreted between 0 and 24 hours after dosing. The excretion varied from 2.7% to 10% (average: 5.2%) of the administered dose on day 2 and only 0.5-1.0% of the dose (average: 0.7%) was excreted on day 7 following treatment with 14C-paraquat dichloride. The total urinary excretion of the radioactivity during the 7-day period was 52.3%-72.3% (average: $58.6 \pm 9.4\%$) of the injected dose. No attempt was made to characterize the radioactivity detected in urine.

Conclusions:

Adult, male Rhesus monkeys excreted in urine 47% of the injected radioactivity during the first 24 hours after exposure. An additional 11% of the radioactive dose was eliminated in urine during the remaining 6 days or the study. The radioactivity was administered i.m. as single doses of ¹⁴C-paraquat dichloride.

Because many experimental details are missing, as was already indicated in the <u>Protocol</u> section, it is difficult to conclude whether this study was carelessly conducted or just carelessly reported.

Classification of the Study: Acceptable as Supplementary (there are no core criteria for this type of a study).

Krystyna K. Locke, Ph.D. Toxicology Branch Hazard Evaluation Division (TS-769) The stock solution contained 2.4 mg of "C-paragnet dichloride (and not 14 C-paragnet ion) / ml.

1) It was reported that 0.25 ml of the stock solution (2.4 mg of paraguet ion/ml.) yielded 4.72 m Ci as paraguet dichloride.

MV of paragnet dichloride 257.2; MV of paragnet ion 186.3

2.4 mg par, ish x 257.2 = 3.313 mg paragrant Cle / int. of the stock solution

0.25 L x 3.313 mg jon. arful = 0.828 mg par. ar (doke injected)

Specific Activity (SA) of the stock solution: 2 pc Ci put or 2 m Ci/m M I m M of grayust dichloride = 257. 2 mg

2.0 m G: = 0.007776 m G: = 7.776 m G: 257.2 mg par. Cl mg par. Cl

Those fore, 0.828 my par. Cl2 x 7.776 pc Gi = 6.44 pc Gi (dose injected if the stock solution contained 2.4 mg par. ion /me).

(1) Assuming that the stock solution contained 2.4 mg of paraguet dichloride / we, then 0.25 ml × 2.4 mg/ml = 0.6 mg (dose injected as paraguat dichloride).

Than, 0.6 mg par. Cl x 7.776 m Ci = 4.67 m Ci (dose _ mg par. ar

injected), which is closen to the reported 4.72 pth than the to the 6.44 pt (coloulated above).

3) Dose of paragnat dichloride injected (in p.z.), calculated from the reported 4.72 p. a.

MU of parequet dichloride 257.2; therefore, | µn = 257.2 µg SA = 2.0 m C: | m H or 2.0 µ C: / µ H

<u>4.72 μ Gi</u> x 1.0 μ M = 2.36 μ M (dose injected)

2.36 µM x 257.2 µg |µM = 607 µg (injected dose as paraquat dichloride)

5

002620

Study Type: Acute Dermal Absorption

Accession Number: 249511

Sponsor: Chevron Chemical Company

Contracting Lab: Howard I. Maibach, M.D.

University of California Medical Center

San Francisco 94143

Date: September 24, 1982

Test Material: 14C-Paraquat Dichloride

Protocol:

Single doses of paraquat dichloride (Specific Activity = 2 mCi/mM; MW 272.2) were applied on the forearms (4.95 uCi), back of the hands (4.70 uCi) and back of the lower legs (5.33 uCi) of 6 healthy, adult male volunteers aged 18 years or older. Each application was made over a 70 cm² area, using 9 ug of paraquat dichloride/cm².* Volunteers were instructed not to wash the application sites for 24 hours following each application. Urine samples were collected at 4, 8 and 12 hours during the first day and then every 24 hours for a total of 5 days. The radioactivity was assayed with a liquid scintillation spectrophotometer, using a 14 C internal standard and a triplicate vial of each sample. Only polystyrene or polypropylene laboratory apparatus was used in this study (paraquat adsorbs to untreated glass). Each application site represented a separate experiment.

The following experimental details were not reported:

- 1. Radiopurity of 14 C-paraquat dichloride and where it was labeled (in the methyl groups or in the ring).
- 2. Who were these volunteers? Were they university students, faculty members and/or hospital staff?
- 3. How old was each volunteer?
- 4. Where did they live during the 5-day test period? At home or at the Medical Center?
- 5. How was the urine preserved and stored before the analysis for $^{14}\mathrm{C?}$
- 6. Were the application sites covered during the 24-hour exposure period?

* There is an error in the <u>Procedures</u> section of the submitted report. According to the author, a stock solution used contained 2.4 mg of paraquat ion/ml. If this were correct, then each application would have contained 11.83 ug of paraquat dichloride/cm² and not 9 ug/cm², as was reported by the author. A stock solution contained, therefore, 2.4 mg of paraquat dicholoride (and not paraquat ion)/ml.

Each 0.25 ml of the same stock solution (volume of a dose), applied on the skin, contained a different number of uCi indicating that the stock solution was being concentrated (due to evaporation of water). The actual numbers of uCi of ^{14}C -paraquat dichloride applied/cm² were as follows: forearm (9.09), hand (8.63) and legs (9.79). Calculations are attached.

Results:

Dermal absorption of 14C-paraquat dichloride by adult, human males was determined by measuring the total amount of 14C excreted in the urine. Each calculated value was then corrected for imcomplete urinary excretion, using data from the study with four Rhesus monkeys where 58.6% of the administered (i.m.) 14C-paraquat dichloride was eliminated in urine.

Irrespective of the site of application, the absorption of paraquat dichloride through the skin was very low. With all application sites, the peak excretion of ¹⁴C in urine occurred between 0 and 24 hours after dosing, when data are expressed as a plot of the percent of the dose excreted/hour versus time. However, inspection of Tables dated 8/16/82, 8/30/82 and 9/13/82 shows that there were wide variations in the amount of urinary ¹⁴C for the same subject and among subjects, for all application sites. These data are summarized below.

Site of Application	Urinary Excretion of 14C (%)*		
	Average	SD**	Range
Forearm	0.293	0.117	0.205-0.519
Back of Hand	0.230	0.078	0.123-0.341
Lower Leg	0.285	0.232	0.052-0.702

^{*} Of the applied dose

^{**} Standard Deviation

Insufficient experimental details preclude further comments on this study.

Conclusion:

14C-Paraquat dichloride, applied on the forearms, hands and lower legs of 6 adult human males, was absorbed very poorly. Dermal absorption of the test material was measured by monitoring urinary excretion of 14C for a total of 5 days after dosing.

Classification of the Study: Acceptable as Supplementary (there are no core criteria for this type of a study).

Krystyna K. Locke, Ph.D. Toxicology Branch Hazard Evaluation Division (TS-769)

OPP:HED:TOX:K.LOCKE:sb 3/21/83 X71511 Rm 824

#m24

Study with human males 002620

1) It was reported that 0.25 ml of the stock solution (2.4 mg of paraguat ion | ml), applied over 70 cm² area, equaled 9 mg of paraguat dichloride / cm², but this is incorrect.

MW of paragrat dichloride 257.2 MW of paragrant ion 186.3

2.4 mg par. ion | ml × $\frac{257.2}{186.3}$ = 3.313 mg of paragnet dichloride | ml

0.25 ml × 3.313 mg/ml = 0.828 mg = 828 mg of paraquit dichloride (dose applied over 70 cm² of the skin on hands, legs or forearms).

828 mg = 11.83 mg/cm², and not 9 mg/cm², as was reported.

- D Assuming that the stock solution contained 2.4 mg of paragust dichloride | ml, then 0.24 mg | ml × 0.25 ml = 0.6 mg = 600 mg was applied over 70 cm² area 600 mg | 70 cm² = 8.6 mg | cm², which is closer to the reported 9 mg | cm² (~ 4.5 % error) than to the colculated (above) 11.83 mg | cm².
- 3) It was reported that 0.25 wh of the stock solution yielded—the following doses of paragnet dichloride: 4.70 µ Ci (applied on hand), 4.95 µ Ci (applied on frearm) and 5.33 µ Ci (applied on leg). Each dose equaled, presumably, 9 µg in of paragnet dichloride of cm².

Each application site represented a separate study and the interval between studies was about 2 weeks. (Tables summarizing results for hands, forearms and legs are dated \$116/82, \$130/82 and 9/13/82, respectively). Because the same dose (0.25 ml) contained more microcuries with time. The stock solution was apparently being concentrated (due to evaporation of water). The actual number of micrograms of paraquet dichloride / cm² was, therefore, as follows:

HAND SA of paraquet dichloride = 2.0 m Ci /mM = 2.0 m Ci /257.2 mg = 7.776 m Ci /mg

4.70 p 6: /70 cm² = 0.0671 p 6: / cm²

0.067/ µ Gi/an² = 0.067/ µ Gi/an² = 8.63 µg/cm² 7.776 µ Gi/1000 µg

FOREARM 4.95 m Gi 170 cm2 = 0.0707 m G/cm2

0.0707 m a: / cm² = 9.09 mg/cm² 7.776 m a: / 1000 mg

LEG 5.33 µ G: 170 cm² = 0.0761 µ G: / cm²

0.076/ Li/cm² = 9.79 mg/cm² 7.776 Li/1000 mg